Abstract:Genetic immunity is a new promising approach for the development of novel tuberculosis vaccines. In this study, it is shown that DNA vaccines expressing the fusion protein of antigen 85B (Ag85B) and early secreted antigenic target 6-kDa antigen (ESAT6) can induce high levels of specific IgG2a antibody subtype in the mice. With the prolongation of postimmunization time, the levels of IgG2a antibody decrease gradually. Although a high-level specific IgG2a antibody subtype is also elicited by classical BCG, the ratio of antibody subtypes IgG2a to IgG1 changes 4weeks after immunization, and IgG1 is gradually shifted to the main antibody subtype. DNA vaccines also elicit cellular immunity as shown by specific spleen lymphocytes proliferation to Ag85B or ESAT6 protein and the production of high levels of IFN-gamma and IL-2, which is similar to that elicited by BCG. Vaccination of mice with DNA vaccines expressing the fusion protein Ag85B-ESAT6 results in a significant level of protection against the subsequent high-dose challenge with virulent Mycobacterium tuberculosis (MTB) H37Rv. Dramatic reduction in the number of MTB colony-forming units in the spleens and lungs is observed. Pathological examination showed that recombinant plasmid and BCG groups have only minor damage and organizational structures that are kept relatively complete, while in the control group, spleens and lungs are damaged seriously. Therefore, although the reducing degree of mycobacterial loads in the organ of mice immunized with recombinant plasmid is not more than that of BCG, through the analysis of pathological changes, we may conclude that the protective effect provided by DNA vaccine expressing the Ag85B-ESAT6 fusion protein is equivalent to that afforded by the classical BCG.

A novel DNA vaccine containing multiple TB-specific epitopes cast in a natural structure elicits enhanced Th1 immunity compared with BCG.

A novel DNA vaccine containing multiple TB-specific epitopes casted in a natural structure (ECANS) confers protective immunity against pulmonary mycobacterial challenge.

Induction of an Immune-Protective T-Cell Repertoire with Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans

Dna Vaccine with Discontinuous T-Cell Epitope Insertions into Hsp65 Scaffold As A Potential Means to Improve Immunogenicity of Multi-Epitope Mycobacterium Tuberculosis Vaccine

Immune Responses and Protective Efficacy of the Gene Vaccine Expressing Ag85B and ESAT6 Fusion Protein Frommycobacterium Tuberculosis

Boosting BCG-primed Mice with Chimeric DNA Vaccine HG856A Induces Potent Multifunctional T Cell Responses and Enhanced Protection Against Mycobacterium Tuberculosis

Immunogenicity of DNA vaccine expressing ESAT6-CFP10 fusion protein of Mycobacterium tuberculosis

Ag85A DNA Vaccination Boosting Enhances BCG Primed-Mice Anti-Tuberculosis T Cell Responses

Vaccination Against Tuberculosis by DNA Injection

Novel Recombinant Bcg Coexpressing Ag85b, Esat-6 And Rv2608 Elicits Significantly Enhanced Cellular Immune And Antibody Responses In C57bl/6 Mice

DNA Vaccines Against Tuberculosis.

Improved Humoral Immunity Against Tuberculosis Esat-6 Antigen By Chimeric Dna Prime And Protein Boost Strategy

Construction of Multivalent DNA Vaccines Formycobacterium Tuberculosis and Its Immunogenicity

Combined DNA Vaccine Encapsulated in Microspheres Enhanced Protection Efficacy Against Mycobacterium Tuberculosis Infection of Mice

The cellular immune response and protective efficacy against tuberculosis infection of a novel mycobacterium tuberculosis DNA vaccine p846

Immunogenicity and Protective Efficacy of a DNA Vaccine Encoding the Fusion Protein of Mycobacterium Heat Shock Protein 65(hsp65) with Human Interleukin‐2 Against Mycobacterium Tuberculosis in BALB/c Mice

Dna Vaccines Against Tuberculosis

A Novel Vaccine P846 Encoding Rv3615c, Mtb10.4, and Rv2660c Elicits Robust Immune Response and Alleviates Lung Injury Induced by Mycobacterium Infection

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

A Heterologous DNA Priming-Mycobacterium Bovis BCG Boosting Immunization Strategy Using Mycobacterial Hsp70, Hsp65, and Apa Antigens Improves Protection Against Tuberculosis in Mice.

Immunogenicity and Protective Efficacy Study Using Combination of Four Tuberculosis Dna Vaccines